WuXi AppTec Addresses Media Speculation on Potential Sale of WuXi ATU
WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359, OTCMKTS: WUXAY), a leading China-based Contract Development...
CRO / CMO / CDMO
Ningbo Menovo Pharmaceutical Partners with Nanjing Huawe Medicine for High-End Product Development
Ningbo Menovo Pharmaceutical Co., Ltd (SHA: 603538) has entered into a strategic partnership with Nanjing...
Tigermed Announces Acquisition of Majority Stake in Shanghai Guanhe Pharmaceutical for CNY 140 Million
Tigermed (SHE: 300347, HKG: 3347) has announced its intention to acquire a 40.5650% stake in...
Signet Therapeutics and Jennio Biotech Join Forces to Advance Tumor Immunotherapy
Signet Therapeutics, a pioneering biopharmaceutical company in China specializing in cancer targeted therapies based on...
Celltrion Inc. Enters CDMO Arena Amid Shifts in Global Biosecurity Landscape
South Korea’s biosimilars giant, Celltrion Inc., is gearing up to expand into the contract development...
Itcure Expands Gene Editing Reach with Collaborations in China’s Biotech Sector
Itcure, a prominent gene editing specialist headquartered in Suzhou, has announced separate strategic collaborations with...
Tigermed Partners with Purpose Africa to Boost Clinical Research and Healthcare Cooperation
Tigermed (SHE: 300347), a leading Contract Research Organization (CRO) in China, has entered into a...
Sinopharm’s InnoStar Bio-tech Becomes First Pharma Company to IPO on STAR in 2024
SHANGHAI—Shanghai InnoStar Bio-tech Co., Ltd., a subsidiary of Sinopharm’s China State Institute of Pharmaceutical Industry...
WuXi Biologics to Acquire Full Control of Vaccine Contract Services Subsidiary for $108.5 Million
HONG KONG—WuXi Biologics (HKG: 2269), a leading global open biopharmaceutical technology platform company, has announced...
WuXi Biologics Reports Flat Revenues with Growth in Non-COVID-19 Projects in 2024H1 Financial Report
WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) from China,...
WuXi XDC Reports 67.6% YOY Revenue Growth and Expands Manufacturing with Singapore Plant
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...
WuXi XDC Accelerates Bioconjugate Drug Development with 67.6% YOY Revenue Increase in H1 2024
HONG KONG—WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi...
Evotec to Cut 400 Jobs Amid R&D Slowdown and Corporate Restructuring
Evotec SE (NASDAQ: EVO), a Germany-based Contract Research and Development Organization (CRO/CDMO), has announced plans...
WuXi Biologics Partners with Medigene for TCR TCE Development in Refractory Tumors
WuXi Biologics (HKG: 2269), a leading Contract Research, Development and Manufacturing Organization (CRDMO) in China,...
WuXi AppTec’s H1 2024 Financials Reflect Decline Amid Biosecure Act Challenges
China-based Contract Development and Manufacturing Organization (CDMO) WuXi AppTec (HKG: 2359) has reported a subdued...
Porton Pharma Solutions Partners with Guangzhou Geneseed Biotech to Advance circRNA Therapies
Porton Pharma Solutions Ltd, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into...
Tigermed Expands Asia Pacific Presence with Acquisition of Japanese CRO Medical Edge
Tigermed (SHE: 300347, HKG: 3347), a leading China-based Contract Research Organization (CRO), has announced the...
WuXi AppTec Spends Over USD 360,000 on US Lobbying Amid Biosecure Act Deliberations
Endpoints News has reported that WuXi AppTec Co., Ltd, (SHA: 603259) a China-based Contract Development...
Lionco Pharmaceutical Partners with Laboratoire Bailly-Creat to Expand Overseas
Shanghai-based Lionco Pharmaceutical Group (SHA: 603669) has entered into a strategic partnership framework agreement with...
Legend Biotech’s Shares Leap on Acquisition Rumors; Parent Genscript Biotech Corp. Follows Suit
Chinese biopharmaceutical firm Legend Biotech (NASDAQ: LEGN), a specialist in chimeric antigen receptor (CAR) T-cell...